Scholarlink

<p>Chronic non-healing wounds typically arise from bacterial adhesion and colonization. Plumbagin (PLB), a secondary metabolite derived from <i>Droseraceae</i>, <i>Plumbaginaceae</i>, <i>and Ebenceae,</i> exhibits potent antibacterial activity. In this study, zeolite imidazole framework-8 (ZIF-8) was utilized to encapsulate Plumbagin, constructing the nanoparticle PLB@ZIF. In both in vitro antibacterial experiments and in vivo wound healing assays<i>,</i> PLB@ZIF demonstrated effective synergistic therapy against methicillin-resistant S. aureus (MRSA) and <i>Escherichia coli </i>(<i>E. coli</i>). In addition, compared to PLB or ZIF-8 alone, PLB@ZIF exhibited superior antibacterial efficacy. These results suggested that ZIF-8 significantly enhances the antibacterial efficiency of Plumbagin in wound healing, highlighting the broad application potential of PLB@ZIF for treating wound infection caused by MRSA and <i>E. coli</i>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Engineering of plumbagin-loaded zeolitic imidazolate frameworks for antibiofilm and infected wound healing

  • 期刊论文

  • 发表日期：

    2025年8月10日

查看全文
  • Kexin Wang,
  • Mingyang Li,
  • Yiming Geng,
  • Xiao Fu,
  • Zhanwei Chen

摘要

Chronic non-healing wounds typically arise from bacterial adhesion and colonization. Plumbagin (PLB), a secondary metabolite derived from Droseraceae, Plumbaginaceae, and Ebenceae, exhibits potent antibacterial activity. In this study, zeolite imidazole framework-8 (ZIF-8) was utilized to encapsulate Plumbagin, constructing the nanoparticle PLB@ZIF. In both in vitro antibacterial experiments and in vivo wound healing assays, PLB@ZIF demonstrated effective synergistic therapy against methicillin-resistant S. aureus (MRSA) and Escherichia coli (E. coli). In addition, compared to PLB or ZIF-8 alone, PLB@ZIF exhibited superior antibacterial efficacy. These results suggested that ZIF-8 significantly enhances the antibacterial efficiency of Plumbagin in wound healing, highlighting the broad application potential of PLB@ZIF for treating wound infection caused by MRSA and E. coli.